The high prevalence of multiple sclerosis greatly influences the growth of the neuromyelitis optica spectrum disorder (NMOSD) market. The expected number of people with MS has increased to 2.8 million in 2020 globally. Clinical development for NMOSD has steadily grown lately; there are three ongoing pipeline drugs in late-stage development. It has been witnessed that the monoclonal antibody drugs segment is anticipated to hold the largest share in this market segment.
Data Bridge Market Research shows that the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market was valued at USD 405.9 million in 2021 and is expected to reach USD 651.84 million by 2029, registering a CAGR of 6.10% during the forecast period of 2022 to 2029.
" Increasing Monoclonal Antibody Drug Approvals Surge the Market Growth"
The growing monoclonal antibody drug approvals and increasing research and development activities by the market players for launching effective treatment options for patients with neuromyelitis optica spectrum disorder are also surging the market growth. For instance, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted market authorization to Horizon's UPLINZA as a monotherapy in 2021. It is used for the treatment of adult patients having neuromyelitis optica spectrum disorder (NMOSD) who tested positive for anti-aquaporin-4 immunoglobulin G ( (AQP4-IgG+) antibodies. Thus, this factor boosts market growth.
What restraints the growth of the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market?
" High Cost of Neuromyelitis Optica Spectrum Disorder (NMOSD)"
The growing high costs associated with R&D activities and the cost associated with new drug development combined with the threat of failure and adverse effects will emerge as one of the main limitations for the market. Neuromyelitis optica spectrum disorder (NMOSD) needs complex drug development processes, necessitating much-advanced diagnostic and treatment equipment and tools. All these major factors impede the growth of the market.
Segmentation: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
The global neuromyelitis optica spectrum disorder (NMOSD) market is segmented on the basis of type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel.
- Based on type, the global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into neuromyelitis optica spectrum disorder with aquaporin-4 antibodies, neuromyelitis optica spectrum disorder without aquaporin-4 antibodies.
- Based on treatment type, the global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into medication, plasma exchange therapy, immunoglobulin therapy.
- Based on route of administration, global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into oral, parenteral, others.
- Based on dosage form, global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into tablets, injections, others
- Based on diagnosis, global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into imaging tests, blood tests, others
- Based on end-users, the global neuromyelitis optica spectrum disorder (NMOSD) market is segmented into hospitals, specialty clinics, homecare, others.
- Based on distribution channel, the global neuromyelitis optica spectrum disorder (NMOSD) market has been bifurcated into hospital pharmacy, retail pharmacy, online pharmacy, others.
Regional Insights: North America is expected to dominate the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
North America dominates the market because of the launch of several new treatment options in this region. Furthermore, increasing healthcare expenditure and the availability of treatment options will further boost the market's growth rate in this region.
Asia-Pacific is expected to grow in 2023-2030 due to the wide presence of generic manufacturers in this region. Furthermore, increasing healthcare infrastructure development and the elderly population will further boost the market's growth rate in this region.
To know more about the study, visit, https://www.databridgemarketresearch.com/reports/global-neuromyelitis-optica-spectrum-disorder-nmosd-market
Recent Developments in Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
- In 2020, the U.S. Food and Drug Administration (FDA) approved Enspryng for treating neuromyelitis optica spectrum disorder (NMOSD) in adults. Enspryng was given fast-track designation, which advances the development and review of drugs needed to treat a serious condition and shows promise of meeting an unmet medical need.
The Prominent Key Players Operating in the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Apotex Inc. (Canada)
- AstraZeneca (U.K.)
- Horizon Therapeutics PLC (Ireland)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Aurobindo Pharma (India)
- Lupin (India)
Above are the key players covered in the report, to know about more and exhaustive list of global neuromyelitis optica spectrum disorder (NMOSD) market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
